Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Fusion Pharmaceuticals, a clinical-stage oncology firm, announced its participation in a fireside chat at the SVB Securities Virtual Global Biopharma Conference scheduled for February 15, 2023, at 12:00 p.m. ET. Key executives, including CEO John Valliant and CSO Christopher Leamon, will present. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Fusion specializes in next-generation radiopharmaceuticals, with ongoing clinical trials for therapies targeting IGF-1R, FGFR3, and NTSR1. Collaborations with AstraZeneca and Merck enhance its pipeline of targeted alpha therapies.

HAMILTON, ON and BOSTON, Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 12:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D, Chief Scientific Officer Christopher Leamon, Ph.D., and President and Chief Business Officer Mohit Rawat.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's first program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 study; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), which has received FDA investigational new drug (IND) clearance and will begin a Phase 1 study. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the company has signed strategic actinium supply agreements with TRIUMF and Niowave, Inc.

Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-svb-securities-global-biopharma-conference-301745038.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When will Fusion Pharmaceuticals present at the SVB Securities Virtual Global Biopharma Conference?

Fusion Pharmaceuticals will present on February 15, 2023, at 12:00 p.m. ET.

Who will represent Fusion Pharmaceuticals during the fireside chat?

CEO John Valliant, CSO Christopher Leamon, and CBO Mohit Rawat will represent Fusion Pharmaceuticals.

How can I watch the Fusion Pharmaceuticals presentation?

The presentation can be viewed via a live webcast on the company's 'Events and Presentations' page.

What is the focus of Fusion Pharmaceuticals?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines.

What are the current clinical trials for Fusion Pharmaceuticals?

Fusion is conducting trials for FPI-1434, FPI-1966, and FPI-2059 targeting various receptors.